Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$21.28
-0.94 (-4.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-104.2M · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.8B
P/E
2128.0x
↑EV/EBITDA
134.7x
↑ROE
0.2%
↓Gross Margin
75.8%
↑Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.4%
FCF CAGR
—
FCF margin
-60.4%
FCF / Net income
-105.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $432.5M · net income $2.5M · FCF $-261.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $432.5M | $432.5M | $607.8M | $556.4M | $349.1M |
| Net Income | $2.5M | $2.5M | $21.1M | $31.7M | $-49.4M |
| EBITDA | $57.6M | $57.6M | $81.2M | $76.8M | $-31.6M |
| EPS | 0.01 | 0.01 | 0.07 | 0.10 | -0.16 |
| Gross Margin | 75.8% | 75.8% | 80.9% | 82.2% | 76.6% |
| Operating Margin | -1.6% | -1.6% | 2.5% | 2.3% | -23.6% |
| Net Margin | 0.6% | 0.6% | 3.5% | 5.7% | -14.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.08 | 0.02 | 0.00 |
| Current Ratio | 4.59 | 4.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-261.4M | $-261.4M | $-104.2M | $-22.0M | $-75.1M |
| Returns | |||||
| ROE | 0.2% | 0.2% | 2.2% | 3.5% | -5.7% |
| Valuation | |||||
| P/E | 2128.00 | 2128.00 | — | — | — |
| EV/EBITDA | 134.74 | 134.74 | — | — | — |
| P/B | 5.47 | 5.47 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | -28.8% | -28.8% | 9.2% | 59.4% | — |
| EPS Growth | -90.5% | -90.5% | -33.5% | 164.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
558.9%
EPS terminal req.
$1.89
Spread vs growth
-649.5%
5Y implied EPS CAGR
222.0%
EPS terminal req.
$2.28
Spread vs growth
-312.5%
10Y implied EPS CAGR
88.2%
EPS terminal req.
$3.68
Spread vs growth
-178.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-44.7%
Start / end P/E
551.8x → 3224.2x
EPS bridge
0.07 → 0.01
Residual
-438.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.